Atritech commences enrollment in WATCHMAN Still left Atrial Appendage Closure Gadget study in AF patients Atritech, Inc http://zudena.com . Gery Tomassoni, Director of Study at Central Baptist Medical center in Lexington, Kentucky enrolled the initial patient in to the PREVAIL study.S. Authorization of the WATCHMAN gadget. Atritech received complete FDA acceptance of its confirmatory research, PREVAIL, in past due September and is likely to total enrollment by mid – 2012. The WATCHMAN gadget is commercially obtainable in Europe and various other major geographies beyond america.
Athersys presents data helping MultiStem programs Athersys, Inc. The results were described in some presentations by leading experts, clinicians and collaborators at the business’s annual Investor/Research & Advancement Day held in NEW YORK. Sponsor disease, ischemic stroke, inflammatory bowel disease and weight problems. ‘This annual event we can share some exciting brand-new data, along with provide important scientific insight and perspective on our technology and recent improvement from crucial thought leaders once we go after our mutual objective of developing fresh therapies to treat sufferers with critically unmet medical requirements,’ stated Gil Van Bokkelen, Ph.D., Chief and Chairman Executive Officer of Athersys.’ Today’s presentations provided a synopsis of Athersys’ relevant therapeutic focus on markets, a explanation of the full total results of inner and collaborative study and clinical programs, and an overview of the development route for several programs.